Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance

Combenefit: an interactive platform for the analysis and visualization of drug combinations

(2016) Giovanni Y. Di Veroli et al.   BIOINFORMATICS

DNA Damage-Induced HSPC Malfunction Depends on ROS Accumulation Downstream of IFN-1 Signaling and Bid Mobilization

(2016) Alpaslan Tasdogan et al.   Cell Stem Cell

Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients

(2016) A. Marcell Szász et al.   Oncotarget

Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria

(2016) Wei Sun et al.   Emerging Microbes & Infections

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

(2015) Shuo-Chieh Wu et al.   CANCER CELL

Targeting JAK kinase in solid tumors: emerging opportunities and challenges

(2015) M Buchert et al.   ONCOGENE

Tissue-aware data integration approach for the inference of pathway interactions in metazoan organisms

(2014) Christopher Y. Park et al.   BIOINFORMATICS

Molecular Pathways: IL11 as a Tumor-Promoting Cytokine--Translational Implications for Cancers

(2014) M. Ernst et al.   CLINICAL CANCER RESEARCH

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

(2013) A. Quintas-Cardama et al.   CLINICAL CANCER RESEARCH

Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells

(2013) Barbara Onnis et al.   JOURNAL OF CLINICAL INVESTIGATION

Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924

(2013) A. A. Jazaeri et al.   MOLECULAR CANCER THERAPEUTICS

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions

(2013) Rossella Marullo et al.   PLoS One

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

(2012) L. C. Hanker et al.   ANNALS OF ONCOLOGY

Allele-Specific p53 Mutant Reactivation

(2012) Xin Yu et al.   CANCER CELL

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

(2011) Alfonso Quintás-Cardama et al.   NATURE REVIEWS DRUG DISCOVERY

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY